$SPRC News

SciSparc Reduces Warrant Exercise Price To $1 Per Share In Inducement Agreement; Expects To Receive Aggregate Gross Proceeds Of ~$405,728 From Exercise Of Existing Warrants

SciSparc: Subsidiary NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

SciSparc Unit NeuroThera Labs Issues Update On Its Clinical Trial Program Evaluating SCI-110 For Treatment Of Tourette Syndrome In Adults; Now Advancing Toward Patient Enrollment In Its Phase IIb Clinical Trial For TS, With Investigational Product Shipments To Study Sites Expected In The Near Term

SciSparc Shifts Focus to Agentic AI, Targeting Cybersecurity and Finance Applications

SciSparc Shifts Strategic Focus To Agentic AI Powered Technologies, Including Cybersecurity And Finance Technologies

SciSparc Agrees to Convert $2.02M Convertible Note Into Ordinary Shares At $1.50/Share

SciSparc Announces Transformation into Agentic AI-Powered Technologies, Including Cybersecurity and Finance Technologies

Why Is SciSparc Stock Gaining Thursday?

SciSparc To Shift Its Strategic Focus Toward Agentic AI-Powered Technologies, Including In Cybersecurity And Finance

SciSparc: Subsidiary NeuroThera Labs’ CliniQuantum Reports Successful Quantum-Enabled Analysis of Billions of Gene Combinations Using Real-World Clinical Data on an S&P 500 Company’s Quantum Architecture

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation For Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1

SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders

SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million